PRAMEF12

Across TCGA pan-cancer cohorts, PRAMEF12 RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated PRAMEF12 data layer compared with 5 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PRAMEF12 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRAMEF12 expression acts as an unfavorable survival marker, although some lineages such as PAAD and LUSC show a favorable association.

UCEC, BLCA, and UCS are the cancer types where PRAMEF12 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	All	0.833	0.921	.001	92	view →
BLCA	OS	Tertile	IV	0.343	0.637	<.001	87	view →
UCS	DFS	Tertile	IV	0.192	0.776	<.001	36	view →
CHOL	OS	Tertile	All	0.122	0.745	<.001	36	view →
PAAD	OS	Tertile	All	0.833	0.342	.003	36	view →
PCPG	OS	Tertile	All	0.407	0.967	<.001	27	view →
DLBC	OS	Tertile	III,IV	0.175	0.874	.025	27	view →
UVM	OS	Tertile	All	0.321	0.695	.028	24	view →
READ	OS	Tertile	IV	0.289	0.899	<.001	18	view →
LAML	DFS	Tertile	All	0.250	0.605	.010	18	view →
SARC	DFS	Tertile	All	0.145	0.429	.009	12	view →
CESC	DFS	Tertile	All	0.377	0.587	.038	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 17 lineages.

PRAMEF12–UCEC (DFS)

Open the UCEC breakdown →